Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Prostatic Neoplasms 179Urinary Bladder Neoplasms 31Carcinoma, Renal Cell 19Kidney Neoplasms 18Breast Neoplasms 13Wilms Tumor 11Neoplasms 10Neoplasm Metastasis 10Lung Neoplasms 9Testicular Neoplasms 8Testicular Germ Cell Tumor 6Melanoma 6Carcinoma, Non-Small-Cell Lung 6Non-Muscle Invasive Bladder Neoplasms 5Lymphoma, Large B-Cell, Diffuse 5Endometrial Neoplasms 5Dendritic Cell Sarcoma, Interdigitating 5Burkitt Lymphoma 5Vaginal Neoplasms 4Uterine Cervical Neoplasms 4Urethral Neoplasms 4Squamous Cell Carcinoma of Head and Neck 4Seminoma 4Sarcoma 4Recurrence 4Rectal Neoplasms 4Radiation Injuries 4Multiple Myeloma 4Lymphoma, Non-Hodgkin 4Lymphoma, Mantle-Cell 4

Interventions

Magnetic Resonance Spectroscopy 5Radiosurgery 4luprolide acetate gel depot 3enzalutamide 3Radiotherapy 3Radiation 3Leuprolide 3Goserelin 3relugolix 2gallium 68 PSMA-11 2bicalutamide 2acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 2Triptorelin Pamoate 2Specimen Handling 2Proton Therapy 2Biopsy 2radium Ra 223 dichloride 1niraparib 1histrelin 1fluciclovine F-18 1flibanserin 1entinostat 1darolutamide 1atezolizumab 1apalutamide 1abiraterone 1X-Rays 1Watchful Waiting 1Surveys and Questionnaires 1Surgical Procedures, Operative 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Prostate Adenocarcinoma × Radiotherapy × Genitourinary × Clear all
NCT03274687 2026-05-20

Hypofractionated Radiation Therapy or Conventional Radiation Therapy After Surgery in Treating Patients With Prostate Cancer

NRG Oncology

Phase 3 Completed
296 enrolled 29 charts
Genitourinary

Prostate Adenocarcinoma

NCT05050084 2026-05-04

Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial

NRG Oncology

Phase 3 Active not recruiting
2,050 enrolled
Genitourinary

Prostate Adenocarcinoma

NCT04175431 2025-12-18

Prostate Specific Membrane Antigen (PSMA) or (FACBC) PET/CT Site-Directed Therapy for Treatment of Prostate Cancer, Flu-BLAST-PC Study

University of Washington

Phase 2 Recruiting
100 enrolled
Genitourinary

Prostate Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡